"Designing Growth Strategies is in our DNA"
The global interventional oncology market size was valued at USD 1.88 billion in 2022. The market is projected to grow from USD 2.02 billion in 2023 to USD 3.45 billion by 2030, exhibiting a CAGR of 7.9% during the forecast period.
Interventional oncology refers to the diagnosis, treatment, and palliation of cancer using minimally invasive procedures performed under image guidance. The increasing cancer incidence amongst the population and the rising healthcare burden caused by these conditions, is expected to boost the demand for novel interventional oncology procedures and approaches for the management of these diseases.
In addition to this, a surge in the number of cancer diagnoses and growing initiatives in terms of research activities among the market players to develop novel therapies for different cancer types is expected to spur the global interventional oncology market growth during the forecast period.
Reduced Number of Patient Visits During Pandemic Slowed Market Growth
The COVID-19 impact on the market growth was negative during the pandemic. The temporary shutdown of hospitals and clinics and the higher focus of healthcare providers to accommodate a large number of patients with respiratory distress due to the COVID-19 infections were the major factors responsible for the negative impact on the market during the pandemic. The lockdown restrictions imposed by the government authorities globally resulted in the cancellation or postponement of oncology treatment, which resulted in the reduced number of patient visits to hospitals and clinics. This resulted in decreased demand for these devices amongst the patient population globally.
Furthermore, several market players experienced a decline in their revenue due to the COVID-19 outbreak. For instance, BD, a major market player, witnessed a decline in its revenue generated by its peripheral interventional sales by 4.0% in 2020, compared to 2019, due to the lower interventional oncology device sales.
However, with the uplifting of lockdown restrictions, the number of hospital visits for cancer diagnostics and treatment significantly increased in 2021, which compensated for the missed appointments for various indications of 2020. Also, few market players witnessed growth in their revenue in 2021 owing to the recovery of the market from the COVID-19 pandemic and increased demand for interventional oncology products. The market is anticipated to witness steady growth prospects during the forecast period.
Growing Adoption of Radioembolization as a Treatment for Oncology to Drive Market Growth
In recent years, the market has seen significant adoption of radioembolization as a treatment for oncology, which is the prominent global interventional oncology market trend. Radioembolization is a minimally invasive procedure that involves the targeted delivery of radioactive microspheres directly into the blood vessels that feed tumors.
Previously, while this method was developed for liver cancer, radioembolization is currently being explored for the treatment of cancers, including colorectal cancer and neuroendocrine tumors. This expansion of indications is expected to drive its adoption in a broader range of cancer, thereby driving market size. The market players are also increasing their focus on the advancements in imaging technology and the development of more precise microspheres for radioembolization to improve the procedure's safety and effectiveness. Such strategic initiatives by the market players increase the adoption of these devices for both patients and healthcare providers.
Request a Free sample to learn more about this report.
Growing Prevalence of Cancer Globally to Propel Market Growth
The growing prevalence of oncology patients suffering from different types of cancer, such as liver cancer, lung cancer, breast cancer, and others among the population, is one of the major factors contributing to the rising patient population globally. However, the prevalence of these oncological conditions is found to be higher in the male population as compared to the female. For instance, in February 2022, according to an article published by the World Health Organization (WHO), breast and lung cancer was found to be 2.26 million and 2.21 million cases, respectively, in 2020, which are the leading types of cancer across the globe.
Thus, these factors, coupled with the increasing focus of the market players to develop and introduce novel drugs and therapies to treat cancer, are expected to boost the demand and adoption of interventional oncology in the market during the forecast period.
Preferential Shift Toward Minimally Invasive Surgical Procedures to Augment Market Growth
There is a growing focus on minimally invasive surgical procedures amongst the patient population owing to their distinct advantages, such as lesser pain, reduced length of hospital stays, and other favorable factors. Moreover, faster recovery, lower risk of complications, and improved precision are some of the additional factors contributing to the rising adoption of these procedures among patients. Minimally invasive surgeries use techniques that limit the size and number of cuts during surgeries and decrease the number of soft-tissue injuries. According to a comparative study published by NCBI in January 2021, the study was on Minimally Invasive Surgical (MIS) procedures and open surgery in China, it was observed that patients who underwent MIS showed lower complications than patients who had undergone open surgery. For instance, in January 2019, according to an article published by the International Federation of Gynecology and Obstetrics (FIGO), the number of women being diagnosed with ovarian cancer is likely to rise to 371,000 new cases by 2035. Such a rising number of patients diagnosed with ovarian cancer is expected to drive the demand for these products during the forecast timeframe.
Additionally, increasing initiatives among governmental and non-governmental organizations to raise awareness about the benefits of minimally invasive surgical procedures are supporting the adoption of these procedures among healthcare providers. Therefore, rising benefits associated with minimally invasive procedures, coupled with rising focus on the development of new products by key players for cancer patients, are driving the global market size.
High Cost and Lack of Specialized Professionals for Oncology Treatment May Limit Market Growth
The high costs associated with interventional oncology treatments have emerged as a significant hindrance that could limit the global market growth. In the treatment, the advanced technology and specialized equipment required for procedures include radiofrequency ablation, microwave ablation, and image-guided therapies. These instruments come with a substantial cost, which restricts hospitals or medical facilities from investing heavily in terms of installing them in their facility.
Furthermore, the lack of specialized professionals to perform minimally invasive oncology procedures is another limiting factor, especially in emerging countries. The developing countries might lack in providing training, as these medical professionals need to undergo extensive training and education, which requires cost and time. Moreover, patients in developing regions with a shortage of specialized professionals may face delays in receiving minimally invasive oncology treatments, thereby negatively impacting the adoption of devices. This hindrance is expected to limit the growth of the market during the forecast period.
Radiation Therapy Devices Segment to Grow Due to the Rising Number of Hospitalizations
Based on product type, the market is divided into radiation therapy devices, ablation devices, and embolization devices. The ablation devices segment is further sub-segmented into microwave ablation, radiofrequency ablation, cryoablation, and others. Furthermore, the embolization devices segment is further segmented into microcatheters and guidewires.
The radiation therapy devices segment held the highest market share in 2022 and is anticipated to grow at a substantial CAGR during the projected period. The segment’s growth is attributed to the rising number of hospitalizations coupled with the increasing prevalence of cancer, such as lung, liver, and kidney cancer.
The embolization devices segment is anticipated to grow at the highest CAGR during the forecast period. The increasing adoption of embolization devices drives the segment growth during the projected period. Moreover, the benefits associated with embolization devices in minimally invasive oncology treatment, such as providing precise and targeted tumor control while minimizing damage to surrounding healthy tissues, drive its demand in the future.
To know how our report can help streamline your business, Speak to Analyst
Liver Cancer Segment to Dominate Owing to the Rising Adoption of Embolization Devices
Based on cancer type, the market is segmented into lung cancer, liver cancer, kidney cancer, and others. Liver cancer held the largest interventional oncology market share in 2022 and is anticipated to expand at a significant CAGR during the projected period. The rising adoption of embolization devices, coupled with the growing preference for minimally invasive procedures in healthcare facilities, is anticipated to contribute to the segment growth during the forecast period. Furthermore, the growing focus of market players to develop advanced liver cancer therapies using interventional devices drives the segment.
The kidney cancer segment is anticipated to grow at the highest CAGR during the projected period, 2023-2030. The segment’s growth is attributed to the rising adoption of radiofrequency ablation devices, such as microwave ablation, radiofrequency ablation, and cryoablation. Furthermore, the increasing prevalence of kidney cancers globally is anticipated to contribute to the segment growth during the projected period.
The lung cancer segment is anticipated to grow at a moderate CAGR during the forecast timeframe. The growth is attributed to the rising cases of lung cancer globally coupled with the growing focus of market players to introduce novel devices for the treatment of lung cancer.
Hospitals Segment to Continue its Dominance Due to Increasing Patient Admissions
By end-user, the market is segmented into hospitals, specialty clinics, and others. The hospitals segment held the largest market share in 2022 and is anticipated to expand at a substantial CAGR during the projected period. The growth is attributed to the rising number of hospital admissions requiring minimally invasive oncology treatment. Moreover, the increasing number of hospitals and increasing footfall of patients in hospitals for cancer treatment is estimated to boost the demand for Interventional Oncology devices in the projected years.
The specialty clinics are expected to grow at the highest CAGR during 2023-2030. The segment’s growth is due to awareness of minimally invasive oncology treatment and rising equipment launches by the market players.
By geography, the market is analyzed across North America, Europe, Asia Pacific, and the rest of the world.
North America Interventional Oncology Market Size, 2022 (USD Billion)
To get more information on the regional analysis of this market, Request a Free sample
North America stood at USD 0.80 billion in 2022 and is expected to dominate the market during the projected period. The increasing adoption of embolization devices and the growing usage of minimally invasive treatment of oncology is projected to augment market growth in the region. Moreover, the rising patient population suffering from cancer, an increase in hospital admissions, and a strong presence of key market players are the other factors estimated to boost market growth across North America.
Europe held the second-largest market share in 2022 and is expected to grow at a moderate CAGR during the projected period. The growth is attributed to the rising prevalence of lung cancer and the rising demand for cancer hospitals across Europe. Furthermore, the rising improvement in healthcare infrastructure and the increasing number of hospitals in the region, is propelling the device’s demand used in the minimally invasive treatment of cancer.
Asia Pacific is anticipated to grow at the highest CAGR during the forecast period. The growth is attributed to the strong focus on healthcare infrastructure improvement and the rising launch of ablation devices in the region.
The market in the rest of the world is estimated to grow at a comparatively lower CAGR during the projected period. The increasing improvement in healthcare infrastructure, rising healthcare expenditures, and growing awareness regarding the treatment of oncology are estimated to drive market growth.
Diversified Product Portfolio of Boston Scientific Corporation to Lead to its Market Dominance
The market is consolidated due to the presence of prominent players with significant market share. Key players, such as Siemens Healthineers, Boston Scientific Corporation, and Terumo Corporation, were the leading market players in 2022.
Boston Scientific Corporation dominated the market for interventional oncology in 2022. The company's diversified product portfolio is one of the key factors contributing to its dominance in the market. Moreover, factors such as better capabilities in research & development, manufacturing, and marketing also strengthen its market share.
Other companies, such as Merit Medical Systems and BD, held substantial market share due to their strong presence in the U.S. and Europe. Furthermore, strategic initiatives, such as product portfolio expansion and new product launches, are expected to increase their market shares in the long run.
An Infographic Representation of Interventional Oncology Market
To get information on various segments, share your queries with us
The global market research report includes the segments of type, cancer type, end-user, and geography. It focuses on industry overviews and market dynamics, such as the drivers, restraints, opportunities, and market trends. Moreover, the report provides information related to key industry developments such as mergers and acquisitions and technological advancements in the market. Furthermore, the report focuses on the incidence of cancer in key countries. In addition, the impact of COVID-19 and the industry overview during the pandemic are covered in the report.
Value (USD billion)
CAGR of 7.9% from 2023-2030
By Cancer Type
Fortune Business Insights says that the global market stood at USD 1.88 billion in 2022 and is projected to reach USD 3.45 billion by 2030.
In 2022, the North American market stood at USD 0.80 billion.
The market is expected to exhibit a CAGR of 7.9% during the forecast period (2023-2030).
The liver cancer segment is projected to lead the market by cancer type.
Key factors, such as rising cases of liver cancer globally, growing initiatives in research activities, growing awareness of cancer care, and growing product launches, such as embolic agents, are expected to drive market growth.
Siemens Healthineers, Boston Scientific Corporation, and Terumo Corporation are the top players in the market.
North America dominated the market in 2022.
“This report is really well done and we really appreciate it! Again, I may have questions as we dig in deeper. Thanks again for some really good work.”- U.S.-based biotechnology company focussing on treatment of chronic pain.
“Kudos to your team. Thank you very much for your support and agility to answer our questions.”- Europe-based provider of solutions to automate data centre operations.
“We appreciate you and your team taking out time to share the report and data file with us, and we are grateful for the flexibility provided to modify the document as per request. This does help us in our business decision making. We would be pleased to work with you again, and hope to continue our business relationship long into the future.”- India-based manufacturer of industrial and specialty intermediates with a strong global presence.
“I want to first congratulate you on the great work done on the Medical Platforms project. Thank you so much for all your efforts.”- One of the largest cosmetics company in the world.
“Thank you very much. I really appreciate the work your team has done. I feel very comfortable recommending your services to some of the other startups that I’m working with, and will likely establish a good long partnership with you.”- U.S. based startup operating in the cultivated meat market.
“We received the below report on the U.S. market from you. We were very satisfied with the report.”- UGlobal hearing aids manufacturer.
“I just finished my first pass-through of the report. Great work! Thank you!”- U.S. based solar racking solutions provider.
“Thanks again for the great work on our last partnership. We are ramping up a new project to understand the imaging and imaging service and distribution market in the U.S.”- World’s leading advisory firm.
“We feel positive about the results. Based on the presented results, we will do strategic review of this new information and might commission a detailed study on some of the modules included in the report after end of the year. Overall we are very satisfied and please pass on the praise to the team. Thank you for the co-operation!”- Germany based machine construction company.
“Thank you very much for the very good report. I have another requirement on cutting tools, paper crafts and decorative items.”- Japanese manufacturing company of stationery products.
“We are happy with the professionalism of your in-house research team as well as the quality of your research reports. Looking forward to work together on similar projects”- One of the Leading Food Companies in Germany
“We appreciate the teamwork and efficiency for such an exhaustive and comprehensive report. The data offered to us was exactly what we were looking for. Thank you!”- Intuitive Surgical
“I recommend Fortune Business Insights for their honesty and flexibility. Not only that they were very responsive and dealt with all my questions very quickly but they also responded honestly and flexibly to the detailed requests from us in preparing the research report. We value them as a research company worthy of building long-term relationships.”- Major Food Company in Japan
“Well done Fortune Business Insights! The report covered all the points and was very detailed. Looking forward to work together in the future”- Ziering Medical
“It has been a delightful experience working with you guys. Thank you Fortune Business Insights for your efforts and prompt response”- Major Manufacturer of Precision Machine Parts in India
“I had a great experience working with Fortune Business Insights. The report was very accurate and as per my requirements. Very satisfied with the overall report as it has helped me to build strategies for my business”- Hewlett-Packard
“This is regarding the recent report I bought from Fortune Business insights. Remarkable job and great efforts by your research team. I would also like to thank the back end team for offering a continuous support and stitching together a report that is so comprehensive and exhaustive”- Global Management Consulting Firm
“Please pass on our sincere thanks to the whole team at Fortune Business Insights. This is a very good piece of work and will be very helpful to us going forward. We know where we will be getting business intelligence from in the future.”- UK-based Start-up in the Medical Devices Sector
“Thank you for sending the market report and data. It looks quite comprehensive and the data is exactly what I was looking for. I appreciate the timeliness and responsiveness of you and your team.”- One of the Largest Companies in the Defence Industry